Oct 13, 2021 / 12:30PM GMT
Operator
Hello, and welcome to the Atara Biotherapeutics Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Eric Hyllengren. Please go ahead.
Eric Hyllengren - Atara Biotherapeutics, Inc. - VP of IR & Finance
Thank you, operator. Good morning, everyone, and welcome to Atara's ATA188 data conference call. Earlier this morning, we issued a press release reporting updated 2-year data from our ongoing Phase I open-label extension study of ATA188 and new magnetization transfer ratio imaging data being presented at ECTRIMS today in an ePoster. This press release and the slides we will be presenting during this call are available in the Investors and Media section of atarabio.com.
Joining me on today's call are Dr. Pascal Touchon, President and Chief Executive Officer; Dr. Jakob Dupont, Executive Vice President and Global Head of Research and Development; Dr. AJ Joshi, Chief Medical Officer; Utpal Koppikar, Chief Financial Officer; and Dr. Doug Arnold of Montreal
Atara Biotherapeutics Inc to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021 Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers